Drugs / Pancreatic Polypeptide
Pancreatic Polypeptide
also known as
Human pancreatic polypeptide · Pancreatic hormone iii · Pancreatic polypeptide (human)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03854708 | Aug 2010 → Mar 2011 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00791076 Comparator | Oct 2007 → Jun 2010 | type 1 diabetes mellitus | Johns Hopkins University | Terminated | No outcome recorded |
| — | NCT07506369 Comparator | Apr → Oct 2026 expected | obesity disorder | University Hospital, Gentofte, Copenhagen | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pancreatic Polypeptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07506369 ↗ |
| Known as | Human pancreatic polypeptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4540843 ↗ |
| Known as | Pancreatic hormone iii | ChEMBL registry synonym — accepted as the source's own label CHEMBL4540843 ↗ |
| Known as | Pancreatic polypeptide (human) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4540843 ↗ |
| Modality | Peptide | “pancreatic polypeptide (PP), a hormone that is naturally produced by the pancreas” NCT00791076 ↗ |
| Route | Intravenous | “was intravenously infused” NCT03854708 ↗ |